[{"tags":["Biopharmaceutical Industry","Financial Markets","Healthcare","Industrials","Stock","Unknown Sector"],"id":27256688,"tickers":["abbv","biib","gild","mkgaf","mrk","nvs","nvsef","pfe","rprx","vrtx","vtnr"],"url":"https://finance.yahoo.com/news/royalty-pharma-announce-second-quarter-201510148.html","description":"NEW YORK, July 20, 2020 -- Royalty Pharma (NASDAQ: RPRX) today announced that it will report its second quarter 2020 financial results on Wednesday, August 12, 2020, before the.","publishedDate":"2020-07-20T20:15:10Z","source":"finance.yahoo.com","title":"Royalty Pharma to Announce Second-Quarter 2020 Financial Results on August 12","crawlDate":"2020-07-20T20:29:34.707159Z"},{"tags":["Biogen","Credit Suisse","ETF","Financial Services","Healthcare","Industrials","Stock","Unknown Sector"],"id":27254056,"tickers":["amgn","amjl","biib","cs","gild","incy","nbix","regn","vrtx","vtnr","xbi"],"url":"https://finance.yahoo.com/news/credit-suisse-upgrades-gilead-remdesivir-153840119.html","description":"The biotech sector is a surefire winner due to a two-pronged benefit from the coronavirus pandemic, according to an analyst at Credit Suisse. Biotechs To Outperform In Q2? The biotech sector is not only the likely source of the solution to the pandemicm but is also fairly immune to the associated headwinds","publishedDate":"2020-07-20T15:38:40Z","source":"finance.yahoo.com","title":"Credit Suisse Upgrades Gilead On Remdesivir Commercial Opportunity","crawlDate":"2020-07-20T18:58:39.932299Z"},{"tags":["Biogen","Consensus Estimate","Healthcare","Stock","Technology","Unknown Sector"],"id":27244976,"tickers":["biib","msft","pfe","rhhby","rhhvf","sny"],"url":"https://finance.yahoo.com/news/biogen-biib-report-q2-earnings-122412169.html","description":"Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Biogen's (BIIB) second-quarter earnings.","publishedDate":"2020-07-20T12:24:12Z","source":"finance.yahoo.com","title":"Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?","crawlDate":"2020-07-20T13:34:33.297889Z"},{"tags":["Analyst Blog","Healthcare","Stock"],"id":27243854,"tickers":["biib","pfe","rhhby","sny"],"url":"https://www.zacks.com/stock/news/1009493/biogen-biib-to-report-q2-earnings-whats-in-the-cards?cid=CS-ZC-FT-analyst_blog%7Cearnings_preview-1009493","description":"Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Biogen's (BIIB) second-quarter earnings.","publishedDate":"2020-07-20T12:24:00Z","source":"zacks.com","title":"Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?","crawlDate":"2020-07-20T13:04:15.020890Z"},{"tags":["Amgn","Biib","Business","ETF","Gild","Healthcare","Hqh","Regn","Stock"],"id":27242554,"tickers":["amgn","biib","gild","hqh","regn"],"url":"https://seekingalpha.com/article/4359332-hqh-attractive-biotech-healthcare-exposure","description":"HQH operates in the healthcare space, and more specifically, in the sub-sector of biotech. The fund has what can be a confusing distribution policy for some newer investors.","publishedDate":"2020-07-20T12:23:23Z","source":"seekingalpha.com","title":"HQH: Attractive Biotech Healthcare Exposure","crawlDate":"2020-07-20T12:25:45.352480Z"},{"tags":["Basic Materials","Communication Services","Consumer Cyclical","Energy","Financial Services","Healthcare","Industrials","Stock","Technology","Unknown Sector"],"id":27243159,"tickers":["algn","amzn","axp","bac","biib","fcx","ftnt","gs","gsbd","gsf","gsj","hal","hbi","hsic","intc","iqnt","jpm","jpm-ws","luv","mhm","mpe","msft","nclh","nflx","snap","swks","tall","twtr","txn","vz","vza","wat"],"url":"https://insights.tradestation.com/2020/07/20/nasdaq-lags-stock-recap-coronavirus/","description":"The S&P 500 rose last week but key technology stocks like Netflix and Amazon.com dragged the Nasdaq-100 lower. Coronavirus cases kept rising.","publishedDate":"2020-07-20T12:23:11Z","source":"insights.tradestation.com","title":"Nasdaq Has Worst Week vs S&P 500 Since 2009 as Netflix Falls","crawlDate":"2020-07-20T12:43:49.809237Z"},{"tags":["Biopharmaceutical Industry","Healthcare","Industrials","Ptc Therapeutics","Rare Diseases","Spinal Muscular Atrophy","Stock","Unknown Sector"],"id":27241707,"tickers":["abbv","biib","gild","mkgaf","mrk","nvs","nvsef","pfe","ptct","rprx","vrtx","vtnr"],"url":"https://finance.yahoo.com/news/royalty-pharma-acquires-royalty-interest-114510176.html","description":"NEW YORK, July 20, 2020 -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. (Nasdaq: PTCT) to acquire a portion of PTC’s royalty.","publishedDate":"2020-07-20T11:45:10Z","source":"finance.yahoo.com","title":"Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics","crawlDate":"2020-07-20T12:05:08.481822Z"},{"tags":["Audit Committee","Board Of Directors","Chief Information Officer","ETF","Florida A&M University","Healthcare","Stock","Unknown Sector"],"id":27247567,"tickers":["act","agn","amgn","azn","biib","mrk","neo","optr","pfe"],"url":"https://finance.yahoo.com/news/neogenomics-announces-board-appointments-110000106.html","description":"FT MYERS, FL / ACCESSWIRE / July 20, 2020 / NeoGenomics, Inc.","publishedDate":"2020-07-20T11:00:00Z","source":"finance.yahoo.com","title":"NeoGenomics Announces Board Appointments","crawlDate":"2020-07-20T14:59:21.839807Z"},{"tags":["Healthcare","Ionis Pharmaceuticals","Multiple Sclerosis","Rare Diseases","Stock"],"id":27240138,"tickers":["akca","biib","ions"],"url":"https://finance.yahoo.com/news/akcea-appoints-senior-vice-president-110000349.html","description":"Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Christophe Hotermans, M.D., Ph.D., has joined the company as senior vice president of global medical affairs where he will lead and evolve the execution of medical strategies, activities","publishedDate":"2020-07-20T11:00:00Z","source":"finance.yahoo.com","title":"Akcea Appoints New Senior Vice President, Global Medical Affairs","crawlDate":"2020-07-20T11:19:22.361327Z"},{"tags":["ETF","Healthcare","Stock","Unknown Sector"],"id":27239432,"tickers":["act","agn","amgn","azn","biib","mrk","neo","optr","pfe"],"url":"https://www.accesswire.com/viewarticle.aspx?id=598018","description":"FT MYERS, FL / ACCESSWIRE / July 20, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today changes in the composition and certain roles ","publishedDate":"2020-07-20T11:00:00Z","source":"accesswire.com","title":"NeoGenomics Announces Board Appointments","crawlDate":"2020-07-20T11:03:46.885812Z"},{"tags":["Alexion Pharmaceuticals","Chief Executive Officer","Corporate Finance","Healthcare","Immunogen","Investor Relations","Stock"],"id":27240029,"tickers":["alxn","biib","imgn"],"url":"https://finance.yahoo.com/news/immunogen-appoints-susan-altschuller-phd-110000549.html","description":"ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer","publishedDate":"2020-07-20T11:00:00Z","source":"finance.yahoo.com","title":"ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer","crawlDate":"2020-07-20T11:16:25.818865Z"},{"tags":["Consumer Cyclical","Healthcare","Industrials","Stock","Technology"],"id":27238285,"tickers":["amzn","biib","cmg","dal","goog","googl"],"url":"https://www.politico.com/newsletters/playbook/2020/07/20/congress-is-back-but-the-leaders-are-still-far-apart-489840","description":"And Nancy Pelosi and Barack Obama raise big money for Democrats.","publishedDate":"2020-07-20T10:30:46.586277Z","source":"politico.com","title":"<![CDATA[Playbook: Congress is back, but the leaders are still far apart]]>","crawlDate":"2020-07-20T10:31:05.376624Z"},{"tags":["09062X10","13F","Biib","Biogen","ETF","Financial Services","Healthcare","Hedge Fund Holdings","Institutional Investor Holdings","Medical","Nasdaq:Biib","Sec Filings","Stock","Unknown Sector"],"id":27239193,"tickers":["bcf","bgio","biib","blk","gs","gsf","gsj"],"url":"https://www.thelincolnianonline.com/2020/07/20/biogen-inc-nasdaqbiib-holdings-cut-by-san-francisco-sentry-investment-group-ca.html","description":"San Francisco Sentry Investment Group CA lowered its holdings in Biogen Inc (NASDAQ:BIIB) by 36.7% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 133 shares of the biotechnology company’s stock after selling 77 shares during the period. San Francisco Sentry Investment Group […]","publishedDate":"2020-07-20T09:58:51Z","source":"thelincolnianonline.com","title":"Biogen Inc (NASDAQ:BIIB) Holdings Cut by San Francisco Sentry Investment Group CA","crawlDate":"2020-07-20T10:58:36.438112Z"},{"tags":["09062X10","Biib","Biogen","Earnings","Financial Services","Healthcare","Medical","Nasdaq:Biib","Stock"],"id":27232291,"tickers":["biib","opy"],"url":"https://www.thelincolnianonline.com/2020/07/20/biogen-biib-to-release-quarterly-earnings-on-wednesday.html","description":"Biogen (NASDAQ:BIIB) is set to release its earnings data before the market opens on Wednesday, July 22nd. Analysts expect Biogen to post earnings of $7.94 per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link. Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, […]","publishedDate":"2020-07-20T06:26:46Z","source":"thelincolnianonline.com","title":"Biogen (BIIB) to Release Quarterly Earnings on Wednesday","crawlDate":"2020-07-20T06:51:13.688378Z"},{"tags":["Alzheimer’S Disease","Dementia Care","Dementias","Healthcare","John A. Hartford Foundation","Milken Institute","Stock"],"id":27229225,"tickers":["biib"],"url":"https://finance.yahoo.com/news/milken-institute-announces-alliance-improve-040100389.html","description":"The Milken Institute Center for the Future of Aging announced today the launch of the Alliance to Improve Dementia Care. The Alliance will seek to transform and improve the complex health and long-term care systems that people at risk for and living with dementia must navigate.","publishedDate":"2020-07-20T04:01:00Z","source":"finance.yahoo.com","title":"Milken Institute Announces New Alliance to Improve Dementia Care","crawlDate":"2020-07-20T04:30:44.669206Z"},{"tags":["Biotech","ETF","Equities","Healthcare","Options","Pharma","Stock","Stocks","Unknown Sector"],"id":27224075,"tickers":["biib","dgx","ew","jazz","jnj","lmat","mrna","mrna","qqq","wst"],"url":"https://talkmarkets.com/content/options/jazz-awaits-fda-nod-for-sleep-disorder-drug-earnings-trickle-in-acell-ipo?post=269771","description":"Biotech stocks advanced in the week ended July 17 thanks to positive broader market sentiment, encouraging news flow on the COVID-19 front, and fairly positive results reported by pharma giant Johnson & Johnson.","publishedDate":"2020-07-19T19:50:31.847838Z","source":"talkmarkets.com","title":"Jazz Awaits FDA Nod For Sleep Disorder Drug, Earnings Trickle In, ACell IPO","crawlDate":"2020-07-19T19:50:37.861668Z"},{"tags":["Biogen Inc","Healthcare","Jazz Pharmaceuticals","Johnson & Johnson","Market Sentiment","Nyse","Stock","Unknown Sector"],"id":27225835,"tickers":["adtx","akus","biib","dgx","eq","ew","fusn","jazz","jnj","lmat","mrna","pypd","wst"],"url":"https://finance.yahoo.com/news/week-ahead-biotech-jazz-awaits-191000352.html","description":"Biotech stocks advanced in the week ended July 17 thanks to positive broader market sentiment, encouraging news flow on the COVID-19 front and fairly positive results reported by pharma giant Johnson & Johnson (NYSE: JNJ).Equillium Inc (NASDAQ: EQ) was among the biggest gainers of the week after a drug","publishedDate":"2020-07-19T19:10:00Z","source":"finance.yahoo.com","title":"The Week Ahead In Biotech: Jazz Awaits FDA Nod For Sleep Disorder Drug, Earnings Trickle In, ACell IPO","crawlDate":"2020-07-19T22:20:24.692013Z"},{"tags":["Communication Services","Consumer Cyclical","Consumer Defensive","Coronavirus Vaccine","ETF","Energy","Financial Services","Healthcare","Industrials","Moderna","Pharmaceutical Companies","Stock","Technology","Unknown Sector","Us House Of Representatives","Vaccine Trials"],"id":27220117,"tickers":["aal","alk","amjl","amzn","axp","azn","biib","ccep","cma","cma-ws","coke","cs","ctas","ctxs","dgx","efx","gs","gsbd","gsf","gsj","hal","hon","intc","iqnt","jnj","jsm","key","ko","kof","lii","lnkd","luv","lvs","mkgaf","mrk","msft","navi","nflx","pfe","pm","sam","slb","swks","t","tall","tdy","trv","txn","unp","vz","vza","whr"],"url":"https://finance.yahoo.com/news/vaccine-manufacturers-testify-before-congress-earnings-bonanza-what-to-know-in-the-week-ahead-150954430.html","description":"Vaccine manufacturers testify before Congress, earnings bonanza: What to know in the week ahead","publishedDate":"2020-07-19T15:09:54Z","source":"finance.yahoo.com","title":"Vaccine manufacturers testify before Congress, earnings bonanza: What to know in the week ahead","crawlDate":"2020-07-19T15:26:09.281279Z"},{"tags":["09062X10","13F","Biib","Biogen","Healthcare","Hedge Fund Holdings","Institutional Investor Holdings","Medical","Nasdaq:Biib","Sec Filings","Stock"],"id":27218827,"tickers":["biib"],"url":"https://www.thelincolnianonline.com/2020/07/19/wedbush-securities-inc-reduces-position-in-biogen-inc-nasdaqbiib.html","description":"Wedbush Securities Inc. lowered its holdings in Biogen Inc (NASDAQ:BIIB) by 11.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,101 shares of the biotechnology company’s stock after selling 261 shares during the period. Wedbush Securities Inc.’s holdings in Biogen were worth $562,000 at the […]","publishedDate":"2020-07-19T13:44:41Z","source":"thelincolnianonline.com","title":"Wedbush Securities Inc. Reduces Position in Biogen Inc (NASDAQ:BIIB)","crawlDate":"2020-07-19T14:05:54.682841Z"},{"tags":["Communication Services","Consumer Cyclical","Consumer Defensive","Energy","Financial Services","Healthcare","Industrials","Investing","Stock","Tech Stocks: Can The Nasdaq Keep Racing Ahead? - Cnn","Technology","Unknown Sector"],"id":27216738,"tickers":["002502","aal","amzn","axp","bac","biib","ccep","coke","db","dtk","hal","hon","intc","iqnt","ko","kof","mat","mhm","mpe","msft","txn","vz","vza","wfc","wfc-ws","whr"],"url":"https://www.cnn.com/2020/07/19/investing/stocks-week-ahead/index.html","description":"The Nasdaq has soared to record highs in recent weeks, significantly outpacing gains on both the S&P 500 and the Dow.","publishedDate":"2020-07-19T12:06:50Z","source":"cnn.com","title":"Can US tech stocks keep racing ahead?","crawlDate":"2020-07-19T12:12:15.727880Z"},{"tags":["09062X10","13F","Biib","Biogen","Financial Services","Healthcare","Hedge Fund Holdings","Institutional Investor Holdings","Medical","Nasdaq:Biib","Sec Filings","Stock","Unknown Sector"],"id":27216596,"tickers":["barl","bcs","biib","ms","msk","mwg","mwo","mwr"],"url":"https://www.thelincolnianonline.com/2020/07/19/parallel-advisors-llc-sells-725-shares-of-biogen-inc-nasdaqbiib.html","description":"Parallel Advisors LLC decreased its position in shares of Biogen Inc (NASDAQ:BIIB) by 28.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,786 shares of the biotechnology company’s stock after selling 725 shares during the quarter. Parallel Advisors LLC’s holdings in Biogen […]","publishedDate":"2020-07-19T11:40:52Z","source":"thelincolnianonline.com","title":"Parallel Advisors LLC Sells 725 Shares of Biogen Inc (NASDAQ:BIIB)","crawlDate":"2020-07-19T12:05:39.973300Z"},{"tags":["09062X10","13F","Biib","Biogen","Financial Services","Healthcare","Hedge Fund Holdings","Institutional Investor Holdings","Medical","Nasdaq:Biib","Sec Filings","Stock"],"id":27215997,"tickers":["biib","c","cs"],"url":"https://www.thelincolnianonline.com/2020/07/19/trust-co-of-vermont-trims-stock-position-in-biogen-inc-nasdaqbiib.html","description":"Trust Co. of Vermont lessened its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 9.1% in the 2nd quarter, HoldingsChannel reports. The firm owned 2,491 shares of the biotechnology company’s stock after selling 250 shares during the quarter. Trust Co. of Vermont’s holdings in Biogen were worth $666,000 as of its most recent filing with […]","publishedDate":"2020-07-19T10:54:50Z","source":"thelincolnianonline.com","title":"Trust Co. of Vermont Trims Stock Position in Biogen Inc (NASDAQ:BIIB)","crawlDate":"2020-07-19T11:34:28.949510Z"},{"tags":["09062X10","Biib","Biogen","Financial Services","Healthcare","Lower Price Target","Medical","Morgan Stanley","Nasdaq:Biib","Stock","Unknown Sector"],"id":27214405,"tickers":["barl","biib","cs","ms","msk","mwg","mwo","mwr"],"url":"https://www.thelincolnianonline.com/2020/07/19/morgan-stanley-cuts-biogen-nasdaqbiib-price-target-to-263-00.html","description":"Biogen (NASDAQ:BIIB) had its target price decreased by Morgan Stanley from $301.00 to $263.00 in a research note issued to investors on Wednesday morning, BenzingaRatingsTable reports. Morgan Stanley currently has an underweight rating on the biotechnology company’s stock. Several other equities research analysts have also issued reports on BIIB. Raymond James lowered shares of Biogen […]","publishedDate":"2020-07-19T09:38:55Z","source":"thelincolnianonline.com","title":"Morgan Stanley Cuts Biogen (NASDAQ:BIIB) Price Target to $263.00","crawlDate":"2020-07-19T10:36:57.215799Z"},{"tags":["09062X10","Biib","Biogen","Financial Services","Healthcare","Medical","Nasdaq:Biib","Oppenheimer Holdings Inc.","Reiterated Rating","Stock","Unknown Sector"],"id":27214402,"tickers":["barl","biib","bk","gs","gsf","gsj","ms","msk","mwg","mwo","mwr","opy","ry"],"url":"https://www.thelincolnianonline.com/2020/07/19/biogen-nasdaqbiib-earns-buy-rating-from-oppenheimer.html","description":"Oppenheimer reiterated their buy rating on shares of Biogen (NASDAQ:BIIB) in a research report report published on Thursday morning, AnalystRatings.com reports. The firm currently has a $325.00 price objective on the biotechnology company’s stock. BIIB has been the subject of a number of other reports. Goldman Sachs Group decreased their price objective on shares of […]","publishedDate":"2020-07-19T09:38:53Z","source":"thelincolnianonline.com","title":"Biogen (NASDAQ:BIIB) Earns Buy Rating from Oppenheimer","crawlDate":"2020-07-19T10:36:49.695763Z"},{"tags":["Aal","Aapl","Aci","Airb","Akus","Amat","Amcx","Amd","Amzn","Anip","Api","Aspu","Atvi","Axp","Azn","Ba","Basic Materials","Bc","Bhp","Biib","Bntx","Business","Cdlyy","Cma","Cmcsa","Cmg","Cof","Colm","Communication Services","Consumer Cyclical","Consumer Defensive","Cp","Crtg","Cwh","Cybe","Cydy","Czr","Dg","Dis","Dkng","Dltr","Dow","Ea","Eadsf","Ebay","Ebon","Ecor","Efx","Ehc","Energy","Eri","Erj","Exas","Fb","Financial Services","Fnjn","Fusn","Ghc","Goog","Gs","Hal","Hbi","Hcsg","Healthcare","Hmi","Hsy","Ibm","Industrials","Ino","Intc","Jamf","Jnj","K","Kin","Kmb","Ko","Lcii","Lmt","Lng","Lrcx","Luv","Mat","Materials","Mbuu","Mnk","Mrk","Mrna","Msci","Msft","Ncmgf","Ndaq","Neph","Nflx","Ngvt","Ntnx","Nvax","Nvda","Patk","Pfe","Pii","Pm","Prnb","Pypd","Rcrt","Rst","Schw","Sgms","Shtdf","Sjm","Snap","Sne","Spce","Spgi","Stock","Stz","T","Technology","Tho","Tkbif","Tmo","Trv","Tsla","Ttwo","Twtr","Txn","Ual","Unknown Sector","Vale","Vfc","Viac","Vrsn","Vsto","Vz","Wgo","Whr","Xauusd:Cur","Xpo"],"id":27195640,"tickers":["aal","aapl","aci","akus","amat","amcx","amzn","anip","aspu","atvi","axp","azn","ba","bhp","bhp","biib","bntx","cma","cmcsa","cmg","cof","colm","crtg","cwh","cybe","cydy","czr","dg","dis","dkng","dltr","dow","dow","dow","eadsf","ebay","ebon","ecor","efx","ehc","eri","erj","exas","fb","fnjn","fusn","ghc","goog","gs","hal","hbi","hcsg","hmi","hsy","ino","intc","jnj","kin","kmb","ko","lcii","lmt","lrcx","luv","mat","mbuu","mnk","mrk","mrna","mrna","msci","msft","ncmgf","ndaq","neph","nflx","ngvt","ntnx","nvax","nvda","patk","pfe","pii","prnb","pypd","rcrt","rst","schw","sgms","shtdf","sjm","snap","sne","spce","spgi","stz","tho","tkbif","trv","tsla","ttwo","twtr","txn","ual","vale","vfc","viac","viac","vrsn","vsto","vz","wgo","whr","xpo"],"url":"https://seekingalpha.com/article/4359185-stocks-to-watch-vaccine-players-earnings-blitz-and-fiscal-debate","description":"Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.","publishedDate":"2020-07-18T12:24:11Z","source":"seekingalpha.com","title":"Stocks To Watch: Vaccine Players, Earnings Blitz And Fiscal Debate","crawlDate":"2020-07-18T12:25:10.207859Z"},{"tags":["09062X10","13F","Biib","Biogen","Financial Services","Healthcare","Hedge Fund Holdings","Institutional Investor Holdings","Medical","Nasdaq:Biib","Sec Filings","Stock"],"id":27195200,"tickers":["bcs","biib"],"url":"https://www.thelincolnianonline.com/2020/07/18/welch-forbes-llc-lowers-holdings-in-biogen-inc-nasdaqbiib.html","description":"Welch & Forbes LLC decreased its holdings in Biogen Inc (NASDAQ:BIIB) by 19.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,651 shares of the biotechnology company’s stock after selling 400 shares during the quarter. Welch & Forbes LLC’s holdings in Biogen […]","publishedDate":"2020-07-18T11:50:41Z","source":"thelincolnianonline.com","title":"Welch & Forbes LLC Lowers Holdings in Biogen Inc (NASDAQ:BIIB)","crawlDate":"2020-07-18T12:02:20.695959Z"},{"tags":["09062X10","Biib","Biogen","Consensus","Financial Services","Healthcare","Medical","Nasdaq:Biib","Ratings","Stock","Unknown Sector"],"id":27193509,"tickers":["barl","biib","ms","msk","mwg","mwo","mwr"],"url":"https://www.thelincolnianonline.com/2020/07/18/7-97-eps-expected-for-biogen-inc-nasdaqbiib-this-quarter.html","description":"Equities research analysts expect Biogen Inc (NASDAQ:BIIB) to post earnings of $7.97 per share for the current quarter, Zacks Investment Research reports. Thirty analysts have made estimates for Biogen’s earnings. The lowest EPS estimate is $6.79 and the highest is $9.07. Biogen posted earnings of $9.15 per share in the same quarter last year, which […]","publishedDate":"2020-07-18T09:54:41Z","source":"thelincolnianonline.com","title":"$7.97 EPS Expected for Biogen Inc (NASDAQ:BIIB) This Quarter","crawlDate":"2020-07-18T10:49:50.173779Z"},{"tags":["Basic Materials","Communication Services","Consumer Cyclical","Consumer Defensive","Earnings","Financial Services","Fiscal Policy","Healthcare","Industrials","Market Insider","Markets","Materials","National Debt","Stock","Stock Markets","Technology","Tiingo Top","U.S. Economy","Unknown Sector","Wall Street"],"id":27176730,"tickers":["aal","aapl","apd","axp","biib","blmn","chkp","csx","dgx","dow","dow","dow","etfc","fb","googl","hon","ibkr","intc","isrg","kmb","ko","lmt","msft","ntrs","phm","snap","syf","trv","tsla","twtr","txn","ual","vz","whr","zion"],"url":"https://www.cnbc.com/2020/07/17/earnings-and-fiscal-debate-could-be-catalysts-for-stocks-in-the-week-ahead.html","description":"Investors are braced for a barrage of earnings news, and the debate in Congress around fiscal stimulus may also be an important catalyst.","publishedDate":"2020-07-17T18:10:24Z","source":"cnbc.com","title":"Earnings and fiscal debate could be catalysts for stocks in the week ahead","crawlDate":"2020-07-17T18:18:51.875862Z"},{"tags":["09062X10","13F","Biib","Biogen","ETF","Financial Services","Healthcare","Hedge Fund Holdings","Institutional Investor Holdings","Medical","Nasdaq:Biib","Sec Filings","Stock","Unknown Sector"],"id":27172391,"tickers":["bcf","bgio","biib","blk","fcnca","fcza","gs","gsf","gsj","sti","stt"],"url":"https://www.thelincolnianonline.com/2020/07/17/first-citizens-bank-trust-co-has-1-01-million-stake-in-biogen-inc-nasdaqbiib.html","description":"First Citizens Bank & Trust Co. trimmed its holdings in Biogen Inc (NASDAQ:BIIB) by 39.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,756 shares of the biotechnology company’s stock after selling 2,450 shares during the period. First Citizens […]","publishedDate":"2020-07-17T15:14:41Z","source":"thelincolnianonline.com","title":"First Citizens Bank & Trust Co. Has $1.01 Million Stake in Biogen Inc (NASDAQ:BIIB)","crawlDate":"2020-07-17T15:33:33.662604Z"},{"tags":["09062X10","13F","Biib","Biogen","Financial Services","Healthcare","Hedge Fund Holdings","Institutional Investor Holdings","Medical","Nasdaq:Biib","Sec Filings","Stock"],"id":27168560,"tickers":["biib","sti"],"url":"https://www.thelincolnianonline.com/2020/07/17/ritholtz-wealth-management-takes-205000-position-in-biogen-inc-nasdaqbiib.html","description":"Ritholtz Wealth Management acquired a new stake in Biogen Inc (NASDAQ:BIIB) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 767 shares of the biotechnology company’s stock, valued at approximately $205,000. Several other large investors also recently modified their holdings of the […]","publishedDate":"2020-07-17T12:44:54Z","source":"thelincolnianonline.com","title":"Ritholtz Wealth Management Takes $205,000 Position in Biogen Inc (NASDAQ:BIIB)","crawlDate":"2020-07-17T13:20:23.341420Z"},{"tags":["Consumer Cyclical","Consumer Defensive","Healthcare","Hedge Fund","Philip Morris","Philip Morris International","S&P 500","Stock","Unknown Sector"],"id":27167012,"tickers":["biib","pm","tall","tsla"],"url":"https://finance.yahoo.com/news/value-investors-buy-philip-morris-122332473.html","description":"Distillate Capital recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Distillate Capital’s U.S. Fundamental Stability & Value (U.S. FSV) strategy's year-to-date decline of 1.19% through Q2 2020, is ahead of the comparable drop of 3.08% for the S&P 500 and 15.1","publishedDate":"2020-07-17T12:23:32Z","source":"finance.yahoo.com","title":"Should Value Investors Buy Philip Morris International (PM) Stock?","crawlDate":"2020-07-17T12:35:16.695739Z"},{"tags":["09062X10","13F","Biib","Biogen","Financial Services","Healthcare","Hedge Fund Holdings","Institutional Investor Holdings","Medical","Nasdaq:Biib","Sec Filings","Stock"],"id":27166851,"tickers":["biib","ry"],"url":"https://www.thelincolnianonline.com/2020/07/17/central-trust-co-sells-45-shares-of-biogen-inc-nasdaqbiib.html","description":"CENTRAL TRUST Co lessened its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 5.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 825 shares of the biotechnology company’s stock after selling 45 shares during the period. CENTRAL TRUST Co’s holdings […]","publishedDate":"2020-07-17T12:04:48Z","source":"thelincolnianonline.com","title":"CENTRAL TRUST Co Sells 45 Shares of Biogen Inc (NASDAQ:BIIB)","crawlDate":"2020-07-17T12:29:11.976087Z"},{"tags":["09062X10","Biib","Biogen","Earnings Estimates","Financial Services","Healthcare","Jefferies Financial Group Inc","Medical","Nasdaq:Biib","Stock","Unknown Sector"],"id":27160744,"tickers":["barl","biib","jef","ms","msk","mwg","mwo","mwr"],"url":"https://www.thelincolnianonline.com/2020/07/17/biogen-inc-nasdaqbiib-to-post-fy2021-earnings-of-33-26-per-share-jefferies-financial-group-forecasts.html","description":"Biogen Inc (NASDAQ:BIIB) – Investment analysts at Jefferies Financial Group dropped their FY2021 earnings per share estimates for shares of Biogen in a research report issued to clients and investors on Monday, July 13th. Jefferies Financial Group analyst M. Yee now forecasts that the biotechnology company will post earnings of $33.26 per share for the […]","publishedDate":"2020-07-17T08:30:44Z","source":"thelincolnianonline.com","title":"Biogen Inc (NASDAQ:BIIB) to Post FY2021 Earnings of $33.26 Per Share, Jefferies Financial Group Forecasts","crawlDate":"2020-07-17T09:17:24.889598Z"},{"tags":["09062X10","Biib","Biogen","ETF","Earnings Estimates","Financial Services","Healthcare","Medical","Nasdaq:Biib","Stock","Unknown Sector","Wedbush"],"id":27157213,"tickers":["bcf","bcs","bgio","biib","blk","jpm","jpm-ws"],"url":"https://www.thelincolnianonline.com/2020/07/17/wedbush-analysts-lift-earnings-estimates-for-biogen-inc-nasdaqbiib.html","description":"Biogen Inc (NASDAQ:BIIB) – Investment analysts at Wedbush lifted their Q4 2020 earnings per share (EPS) estimates for shares of Biogen in a note issued to investors on Tuesday, July 14th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings of $7.16 per share for the quarter, up from their previous […]","publishedDate":"2020-07-17T06:34:41Z","source":"thelincolnianonline.com","title":"Wedbush Analysts Lift Earnings Estimates for Biogen Inc (NASDAQ:BIIB)","crawlDate":"2020-07-17T07:01:37.777528Z"},{"tags":["09062X10","13F","Biib","Biogen","Financial Services","Healthcare","Hedge Fund Holdings","Institutional Investor Holdings","Medical","Nasdaq:Biib","Sec Filings","Stock","Unknown Sector"],"id":27149422,"tickers":["biib","jpm","jpm-ws"],"url":"https://www.thelincolnianonline.com/2020/07/16/biogen-inc-nasdaqbiib-shares-sold-by-wesbanco-bank-inc.html","description":"Wesbanco Bank Inc. reduced its position in shares of Biogen Inc (NASDAQ:BIIB) by 4.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,275 shares of the biotechnology company’s stock after selling 200 shares during the period. Wesbanco Bank Inc.’s holdings in Biogen were […]","publishedDate":"2020-07-16T22:26:52Z","source":"thelincolnianonline.com","title":"Biogen Inc (NASDAQ:BIIB) Shares Sold by Wesbanco Bank Inc.","crawlDate":"2020-07-16T22:52:47.215738Z"},{"tags":["Financial Services","Healthcare","Stock"],"id":27148493,"tickers":["acad","biib","opy"],"url":"https://www.smarteranalyst.com/new-blurbs/oppenheimer-remains-a-buy-on-biogen-biib/","description":"Oppenheimer analyst Jay Olson maintained a Buy rating on Biogen (BIIB) today and set a price target of $325.00. The company's shares closed last Thursday","publishedDate":"2020-07-16T21:08:59Z","source":"smarteranalyst.com","title":"Oppenheimer Remains a Buy on Biogen (BIIB)","crawlDate":"2020-07-16T22:05:49.504440Z"},{"tags":["Healthcare","Stock","Top Market News"],"id":27150898,"tickers":["acad","biib"],"url":"https://www.analystratings.com/articles/oppenheimer-remains-a-buy-on-biogen-biib/","description":"Oppenheimer analyst\nJay Olson\nmaintained a\nBuy\nrating on Biogen (\nBIIB\n–\nResearch Report\n) today and set a price target of\n$325.00\n. The company’s shares closed last Thursday at $279.54.\nAccording to\nTipRanks.com\n, Olson has 0 stars on 0-5 stars rank","publishedDate":"2020-07-16T21:08:54Z","source":"analystratings.com","title":"Oppenheimer Remains a Buy on Biogen (BIIB)","crawlDate":"2020-07-17T00:16:44.256644Z"},{"tags":["All News And Stock Ideas","Biotech And Pharma Stock News","Healthcare","Stock","Technology"],"id":27150148,"tickers":["aciu","biib","jnj"],"url":"https://www.investors.com/news/technology/alzheimers-treatment-study-prods-biotech-company-ac-immune/","description":"Shares of AC Immune surged in massive volume Thursday after the small biotech company began dosing patients with an Alzheimer's treatment.","publishedDate":"2020-07-16T20:25:20Z","source":"investors.com","title":"AC Immune Stock Catapults To Two-Year High On Alzheimer's News","crawlDate":"2020-07-16T23:31:38.153237Z"},{"tags":["Biogen Inc.","Consumer Cyclical","Consumer Defensive","Healthcare","Hedge Fund","S&P 500","Stock","Unknown Sector"],"id":27141073,"tickers":["biib","pm","tall","tsla"],"url":"https://finance.yahoo.com/news/value-investors-buy-biogen-biib-172615160.html","description":"Distillate Capital recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Distillate Capital’s U.S. Fundamental Stability & Value (U.S. FSV) strategy's year-to-date decline of 1.19% through Q2 2020, is ahead of the comparable drop of 3.08% for the S&P 500 and 15.1","publishedDate":"2020-07-16T17:26:15Z","source":"finance.yahoo.com","title":"Should Value Investors Buy Biogen (BIIB) Stock?","crawlDate":"2020-07-16T17:48:15.636497Z"},{"tags":["Clinical Study","Gilead Sciences","Healthcare","Inc.","Phase Iii","Stock","United States","Unknown Sector"],"id":27136423,"tickers":["alxn","amgn","bgne","biib","esaly","gild","regn","rigl"],"url":"https://finance.yahoo.com/news/biotech-stock-roundup-gild-mrna-143102458.html","description":"The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.","publishedDate":"2020-07-16T14:31:02Z","source":"finance.yahoo.com","title":"Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More","crawlDate":"2020-07-16T15:32:16.515764Z"},{"tags":["Analyst Blog","Healthcare","Stock","Unknown Sector"],"id":27135968,"tickers":["amgn","bgne","biib","eq","gild","mrna","mrna","rigl"],"url":"https://www.zacks.com/stock/news/1006597/biotech-stock-roundup-gild-mrna-give-coronavirus-treatment-updates-amp-more?cid=CS-ZC-FT-analyst_blog%7Cstock_roundup-1006597","description":"The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.","publishedDate":"2020-07-16T14:31:00Z","source":"zacks.com","title":"Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More","crawlDate":"2020-07-16T15:19:21.927259Z"},{"tags":["Cancer Patients","Chief Executive Officer","Healthcare","Hematopoietic Stem Cells","Stock","Treatment Of Cancer","Unknown Sector"],"id":27129322,"tickers":["biib","idix","mkgaf","mrk"],"url":"https://finance.yahoo.com/news/vor-biopharma-appoints-daniella-beckman-120000800.html","description":"Vor Biopharma today announced the appointment of Daniella Beckman, Chief Financial Officer at Tango Therapeutics, to its Board of Directors.","publishedDate":"2020-07-16T12:00:00Z","source":"finance.yahoo.com","title":"Vor Biopharma Appoints Daniella Beckman to its Board of Directors","crawlDate":"2020-07-16T12:13:31.282380Z"},{"tags":["09062X10","Biib","Biogen","Earnings Estimates","Financial Services","Healthcare","Jefferies Financial Group Inc","Medical","Nasdaq:Biib","Stock"],"id":27120047,"tickers":["biib","jef","opy"],"url":"https://www.thelincolnianonline.com/2020/07/16/biogen-inc-expected-to-post-q1-2021-earnings-of-8-54-per-share-nasdaqbiib.html","description":"Biogen Inc (NASDAQ:BIIB) – Analysts at Jefferies Financial Group issued their Q1 2021 EPS estimates for Biogen in a research report issued on Monday, July 13th. Jefferies Financial Group analyst M. Yee expects that the biotechnology company will post earnings of $8.54 per share for the quarter. Jefferies Financial Group also issued estimates for Biogen’s […]","publishedDate":"2020-07-16T06:16:43Z","source":"thelincolnianonline.com","title":"Biogen Inc Expected to Post Q1 2021 Earnings of $8.54 Per Share (NASDAQ:BIIB)","crawlDate":"2020-07-16T06:57:14.504247Z"},{"tags":["09062X10","Biib","Biogen","Earnings Estimates","Healthcare","Medical","Nasdaq:Biib","Stock","Wedbush"],"id":27118156,"tickers":["biib"],"url":"https://www.thelincolnianonline.com/2020/07/16/q2-2020-eps-estimates-for-biogen-inc-nasdaqbiib-decreased-by-wedbush.html","description":"Biogen Inc (NASDAQ:BIIB) – Investment analysts at Wedbush dropped their Q2 2020 earnings per share estimates for Biogen in a report released on Tuesday, July 14th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings of $7.72 per share for the quarter, down from their previous forecast of $7.83. Wedbush has […]","publishedDate":"2020-07-16T05:28:52Z","source":"thelincolnianonline.com","title":"Q2 2020 EPS Estimates for Biogen Inc (NASDAQ:BIIB) Decreased by Wedbush","crawlDate":"2020-07-16T05:51:20.482635Z"},{"tags":["Biib","Business","Healthcare","Ions","Stock"],"id":27111360,"tickers":["biib","ions"],"url":"https://seekingalpha.com/article/4358715-ionis-is-long-on-neurological-medicines-pipeline","description":"Ionis is the leader in antisense RNA technology. Neurological medicines are a key part of its pipeline.","publishedDate":"2020-07-15T23:28:20Z","source":"seekingalpha.com","title":"Ionis Is A Long On Neurological Medicines Pipeline","crawlDate":"2020-07-15T23:32:42.888923Z"},{"tags":["Biogen Inc","Financial Services","Healthcare","Matthew Harrison","Stock","Unknown Sector"],"id":27113131,"tickers":["barl","biib","ms","msk","mwg","mwo","mwr","myl"],"url":"https://finance.yahoo.com/news/4-ways-biogens-tecfidera-generic-215540546.html","description":"Biogen Inc (NASDAQ: BIIB) is caught in more than one legal wrangle with generic companies over patents related to its key multiple sclerosis drug Tecfidera, which was approved by the FDA in March 2013.The Biogen Analyst: Morgan Stanley analyst Matthew Harrison has an Underweight rating on Biogen with","publishedDate":"2020-07-15T21:55:40Z","source":"finance.yahoo.com","title":"4 Ways Biogen's Tecfidera Generic Battle Could Play Out For The Stock","crawlDate":"2020-07-16T01:18:30.266207Z"},{"tags":["All News And Stock Ideas","Biotech And Pharma Stock News","Coronavirus","Evergreen","Healthcare","Stock","Stocks To Buy Or Sell","Technology"],"id":27102932,"tickers":["azn","biib","ino","jnj","pfe","regn"],"url":"https://www.investors.com/news/technology/ino-stock-buy-now/","description":"Inovio stock is among the many companies targeting a coronavirus vaccine. But INO stock is volatile and has a weak history. Is the biotech stock a safe bet?","publishedDate":"2020-07-15T12:00:07Z","source":"investors.com","title":"Should Inovio Be On Your Buy List As It Tackles A Coronavirus Vaccine?","crawlDate":"2020-07-15T17:55:40.370233Z"},{"tags":["Biib","Brk-A","Brk-B","Consumer Cyclical","Consumer Defensive","Financial Services","Gs","Healthcare","Ko","Kr","Siri","Stock","Technology","Unknown Sector","Vrsn"],"id":27091101,"tickers":["biib","brk-a","brk-b","ccep","coke","gs","gsbd","gsf","gsj","ko","kof","kr","pep","siri","vrsn"],"url":"https://247wallst.com/investing/2020/07/15/6-warren-buffett-stocks-that-could-soar-as-2021-approaches/","description":"24/7 Wall St. looks at some potential winners among Warren Buffett’s holdings. See why they could rally headed toward 2021 and beyond.","publishedDate":"2020-07-15T11:28:49Z","source":"247wallst.com","title":"6 Warren Buffett Stocks That Could Soar as 2021 Approaches","crawlDate":"2020-07-15T11:57:44.340565Z"},{"tags":["Healthcare","Immuno-Oncology","News","Oncology","Sales And Marketing","Scholar Rock","Spinal Muscular Atrophy","Stock","Tony Kingsley","Unknown Sector"],"id":27086919,"tickers":["biib","bmy","jnj","mdco","nvs","nvsef"],"url":"https://pharmaphorum.com/news/ex-taris-ceo-tony-kingsley-claims-tenure-as-scholar-rocks-new-ceo/","description":"After more than eight years at the helm of US biotech Scholar Rock, Nagesh Mahanthappa is standing down","publishedDate":"2020-07-15T09:25:07Z","source":"pharmaphorum.com","title":"Ex-Taris CEO Tony Kingsley claims tenure as Scholar Rock’s new CEO","crawlDate":"2020-07-15T09:26:49.838306Z"},{"tags":["Bi Graphics","Bi Prime","Coronavirus","Dispensed","Financial Services","Health","Healthcare","Science","Stock","Technology","Unknown Sector","Vaccine"],"id":27075835,"tickers":["alny","amgn","barl","biib","gcvrz","gild","glaxf","gsk","jnj","lly","mkgaf","mrk","mrna","ms","msft","msk","mwg","mwo","mwr","pfe","regn","sny","tak","tkphf"],"url":"https://www.businessinsider.com/wuhan-coronavirus-treatments-vaccine-jj-regeneron-gilead-2020-2","description":"The coronavirus pandemic has infected millions of people across the world. Here are the top research efforts for vaccines and treatments.","publishedDate":"2020-07-14T21:15:00Z","source":"businessinsider.com","title":"How 13 top drugmakers are sprinting to develop a coronavirus vaccine or treatment that can halt this pandemic","crawlDate":"2020-07-14T21:19:19.656021Z"},{"tags":["Analyst Blog","Healthcare","Stock","Unknown Sector"],"id":27063405,"tickers":["amgn","biib","esaly","nvs","rhhby"],"url":"https://www.zacks.com/stock/news/1003653/biogeneisais-new-ban2401-study-for-alzheimers-begins?cid=CS-ZC-FT-analyst_blog%7Ccompany_news_-_medical_sector-1003653","description":"A new phase III study has been initiated to evaluate Biogen (BIIB) and Eisai's BAN2401 to treat preclinical Alzheimer's disease.","publishedDate":"2020-07-14T12:30:00Z","source":"zacks.com","title":"Biogen/Eisai's New BAN2401 Study for Alzheimer's Begins","crawlDate":"2020-07-14T13:05:19.307808Z"},{"tags":["Biotech","Fibrosis","Gilead Sciences","Healthcare","Immuno-Oncology","Janssen","Scholar Rock","Stock","Tiingo Top"],"id":27062661,"tickers":["biib","gild","mdco"],"url":"https://www.fiercebiotech.com/biotech/nagesh-mahanthappa-graduates-from-scholar-rock-hires-taris-ceo-tony-kingsley-as-new-chief","description":"After eight years at the helm, Scholar Rock’s founding CEO Nagesh Mahanthappa, Ph.D., is stepping down from the biotech to become its scientific adviser.","publishedDate":"2020-07-14T12:19:26Z","source":"fiercebiotech.com","title":"Mahanthappa graduates from Scholar Rock, hires Taris CEO Kingsley as new chief","crawlDate":"2020-07-14T12:37:34.421381Z"},{"tags":["09062X10","13F","Biib","Biogen","Financial Services","Healthcare","Hedge Fund Holdings","Institutional Investor Holdings","Medical","Nasdaq:Biib","Sec Filings","Stock","Unknown Sector"],"id":27061894,"tickers":["bcs","biib","jpm","jpm-ws","opy"],"url":"https://www.thelincolnianonline.com/2020/07/14/ifm-investors-pty-ltd-has-3-48-million-stock-holdings-in-biogen-inc-nasdaqbiib.html","description":"IFM Investors Pty Ltd reduced its stake in Biogen Inc (NASDAQ:BIIB) by 29.5% during the second quarter, Holdings Channel.com reports. The fund owned 13,004 shares of the biotechnology company’s stock after selling 5,437 shares during the period. IFM Investors Pty Ltd’s holdings in Biogen were worth $3,479,000 at the end of the most recent quarter. […]","publishedDate":"2020-07-14T11:52:41Z","source":"thelincolnianonline.com","title":"IFM Investors Pty Ltd Has $3.48 Million Stock Holdings in Biogen Inc (NASDAQ:BIIB)","crawlDate":"2020-07-14T12:09:38.018782Z"},{"tags":["Healthcare","Stock","Unknown Sector"],"id":27061758,"tickers":["biib","esaly"],"url":"https://www.smarteranalyst.com/yahoo/biogen-eisai-start-new-phase-3-trial-for-pre-clinical-alzheimers-disease/","description":"Biogen (BIIB), in collaboration with Eisai, and the Alzheimer’s Clinical Trials Consortium, has initiated a new global Phase 3 clinical study (AHEAD 3-45)","publishedDate":"2020-07-14T11:37:55Z","source":"smarteranalyst.com","title":"Biogen, Eisai Start New Phase 3 Trial For Pre-clinical Alzheimer’s Disease","crawlDate":"2020-07-14T12:06:48.717292Z"},{"tags":["Aducanumab","Alzheimer'S","Biogen","Eisai","Healthcare","News","R&D","Stock","Unknown Sector"],"id":27058715,"tickers":["biib","esaly"],"url":"https://pharmaphorum.com/news/biogen-and-eisai-trial-drug-in-asymptomatic-alzheimers-disease/","description":"Biogen and Eisai have begun a new phase 3 study testing an Alzheimer’s antibody drug aimed at patients without symptoms but with elevated levels of amyloid in their brains, the protein aggregate that is thought to cause the disease. ","publishedDate":"2020-07-14T10:44:37Z","source":"pharmaphorum.com","title":"Biogen and Eisai trial drug in asymptomatic Alzheimer’s disease","crawlDate":"2020-07-14T10:46:41.153255Z"},{"tags":["09062X10","13F","Biib","Biogen","Financial Services","Healthcare","Hedge Fund Holdings","Institutional Investor Holdings","Medical","Nasdaq:Biib","Sec Filings","Stock","Unknown Sector"],"id":27060514,"tickers":["barl","biib","jpm","jpm-ws","ms","msk","mwg","mwo","mwr"],"url":"https://www.thelincolnianonline.com/2020/07/14/investment-house-llc-sells-75-shares-of-biogen-inc-nasdaqbiib.html","description":"Investment House LLC lessened its position in Biogen Inc (NASDAQ:BIIB) by 1.1% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 6,514 shares of the biotechnology company’s stock after selling 75 shares during the period. Investment House LLC’s holdings in Biogen were worth $1,743,000 as of its most recent filing with the Securities and Exchange […]","publishedDate":"2020-07-14T10:32:46Z","source":"thelincolnianonline.com","title":"Investment House LLC Sells 75 Shares of Biogen Inc (NASDAQ:BIIB)","crawlDate":"2020-07-14T11:31:27.402936Z"},{"tags":["Biib","Business","Esalf","Esaly","Healthcare","Stock","Unknown Sector"],"id":27057749,"tickers":["biib","esalf","esaly"],"url":"https://seekingalpha.com/news/3590882-eisai-and-biogen-launch-phase-3-ban2401-program-in-asymptomatic-alzheimers-disease","description":"Eisai (OTCPK:ESALF), in collaboration with Alzheimer's Clinical Trials Consortium and Biogen (NASDAQ:BIIB), has initiated a new global Phase 3 clinical study (AHEAD 3-45) with BAN2401, an anti-amyloid beta (Aβ) protofibril antibody.The study will evaluate the therapeutic effect of BAN2401 on the progression of Alzheimer's disease in individuals in preclinical (asymptomatic) stages of the disease.The AHEAD 3-45 program consists of two trials, A3 and A45, which aim to evaluate the potential of BAN2401 to reduce accumulation of harmful amyloid beta aggregates in the brain and prevent cognitive decline.A total of 1400 participants will be enrolled in the study.","publishedDate":"2020-07-14T10:17:23Z","source":"seekingalpha.com","title":"Eisai and Biogen launch Phase 3 BAN2401 program in asymptomatic alzheimer's disease","crawlDate":"2020-07-14T10:23:55.662974Z"},{"tags":["Biib","Business","Gild","Healthcare","Pfe","Sgmo","Stock"],"id":27040519,"tickers":["biib","gild","pfe","sgmo"],"url":"https://seekingalpha.com/article/4358196-sangamo-h2-2020-preview","description":"The Biogen collaboration was completed in 2Q.  Cash is now expected to fund operations beyond BLA timing for Hemophilia A.","publishedDate":"2020-07-13T17:58:52Z","source":"seekingalpha.com","title":"Sangamo H2 2020 Preview","crawlDate":"2020-07-13T18:09:14.119823Z"},{"tags":["Biib","Business","Gild","Healthcare","Pfe","Sgmo","Stock"],"id":27040187,"tickers":["biib","gild","pfe","sgmo"],"url":"https://seekingalpha.com/article/4358196-sangamo-2h-2020-preview","description":"The Biogen collaboration was completed in 2Q.  Cash is now expected to fund operations beyond BLA timing for Hemophilia A.","publishedDate":"2020-07-13T17:58:52Z","source":"seekingalpha.com","title":"Sangamo 2H 2020 Preview","crawlDate":"2020-07-13T18:01:02.161781Z"},{"tags":["Alxn","Amgn","Biib","Gild","Healthcare","Mnkd","Stock"],"id":27034208,"tickers":["alxn","amgn","biib","gild","mnkd"],"url":"https://247wallst.com/healthcare-business/2020/07/13/short-sellers-cant-make-up-their-minds-on-big-biotechs/","description":"The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.","publishedDate":"2020-07-13T13:43:43Z","source":"247wallst.com","title":"Short Sellers Can’t Make Up Their Minds on Big Biotechs","crawlDate":"2020-07-13T13:58:01.424879Z"},{"tags":["Financial Investment","Healthcare","Live Stock Market","Live Stock Market Feeds","Stock","Stock Market","Stock Market Alerts"],"id":27046832,"tickers":["biib"],"url":"https://thefly.com/permalinks/entry.php/id3124687/BIIB;ESALY-Biogen-initiates-new-phase--study-of-BAN-in-preclinical-AD","description":"Biogen initiates new phase 3 study of BAN2401 in preclinical AD BIIB ESALY","publishedDate":"2020-07-13T12:36:11Z","source":"thefly.com","title":"Biogen initiates new phase 3 study of BAN2401 in preclinical AD BIIB;ESALY","crawlDate":"2020-07-13T23:37:02.788843Z"},{"tags":["09062X10","Biib","Biogen","Financial Services","Goldman Sachs Group Inc","Healthcare","Lower Price Target","Medical","Nasdaq:Biib","Stock","Unknown Sector"],"id":27032524,"tickers":["barl","biib","gs","gsf","gsj","ms","msk","mwg","mwo","mwr"],"url":"https://www.thelincolnianonline.com/2020/07/13/goldman-sachs-group-lowers-biogen-nasdaqbiib-price-target-to-257-00.html","description":"Biogen (NASDAQ:BIIB) had its target price dropped by stock analysts at Goldman Sachs Group from $300.00 to $257.00 in a research report issued on Monday, The Fly reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. Goldman Sachs Group’s price objective points to a potential downside of 7.85% from the company’s […]","publishedDate":"2020-07-13T12:08:50Z","source":"thelincolnianonline.com","title":"Goldman Sachs Group Lowers Biogen (NASDAQ:BIIB) Price Target to $257.00","crawlDate":"2020-07-13T12:54:59.107670Z"},{"tags":["Financial Investment","Financial Services","Healthcare","Live Stock Market","Live Stock Market Feeds","Stock","Stock Market","Stock Market Alerts","Unknown Sector"],"id":27028902,"tickers":["biib","gs","gsbd","gsf","gsj"],"url":"https://thefly.com/permalinks/entry.php/id3124101/BIIB-Biogen-price-target-lowered-to--from--at-Goldman-Sachs","description":"Biogen price target lowered to $257 from $300 at Goldman Sachs Goldman Sachs BIIB","publishedDate":"2020-07-13T11:08:07.555883Z","source":"thefly.com","title":"Biogen price target lowered to $257 from $300 at Goldman Sachs BIIB","crawlDate":"2020-07-13T11:08:14.609768Z"},{"tags":["Als\\","Amyotrophic Lateral Sclerosis\\","Biogen\\","Healthcare","Mnd\\","Motor Neurone Disease\\","Sod-1","Stock","Tofersen\\"],"id":27029799,"tickers":["biib"],"url":"http://www.pharmatimes.com/news/experimental_motor_neurone_disease_therapy_shows_early_promise_1344775","description":"Phase I/II study results demonstrate proof-of-concept and proof-of-biology of tofersen","publishedDate":"2020-07-13T10:12:21Z","source":"pharmatimes.com","title":"Experimental motor neurone disease therapy shows early promise","crawlDate":"2020-07-13T11:32:48.058664Z"},{"tags":["09062X10","Biib","Biogen","Healthcare","Medical","Nasdaq:Biib","Reiterated Rating","Stock","William Blair"],"id":27025059,"tickers":["biib"],"url":"https://www.thelincolnianonline.com/2020/07/13/william-blair-reaffirms-hold-rating-for-biogen-nasdaqbiib.html","description":"William Blair reissued their hold rating on shares of Biogen (NASDAQ:BIIB) in a research note issued to investors on Friday, AnalystRatings.com reports. Other equities analysts have also issued research reports about the stock. Stifel Nicolaus reduced their target price on shares of Biogen from $296.00 to $294.00 and set a hold rating on the stock […]","publishedDate":"2020-07-13T08:28:45Z","source":"thelincolnianonline.com","title":"William Blair Reaffirms \"Hold\" Rating for Biogen (NASDAQ:BIIB)","crawlDate":"2020-07-13T09:06:11.880290Z"},{"tags":["Biib","Biogen","Cory Kasimov","ETF","Financial Services","Healthcare","Nasdaq:Biib","Stock","Unknown Sector"],"id":27002298,"tickers":["alxn","amjl","biib","bmrn","cs","rare"],"url":"https://www.markets.co/biogen-biib-gets-a-hold-rating-from-j-p-morgan/260805/","description":"In a report issued on July 8, Cory Kasimov from J.P. Morgan maintained a Hold rating on Biogen (BIIB –","publishedDate":"2020-07-12T09:14:40Z","source":"markets.co","title":"Biogen (BIIB) Gets a Hold Rating from J.P. Morgan","crawlDate":"2020-07-12T09:20:39.795126Z"},{"tags":["Canadian National Railway","Consumer Cyclical","Financial Services","Financials","Healthcare","Hedge Funds","Industrials","Institutional Investors","Percentage Points","Stock","Technology"],"id":26994272,"tickers":["biib","bkng","bx","cni","luk","now"],"url":"https://finance.yahoo.com/news/did-hedge-funds-call-canadian-224520850.html","description":"How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually","publishedDate":"2020-07-11T22:45:20Z","source":"finance.yahoo.com","title":"Did Hedge Funds Make The Right Call On Canadian National Railway Company (CNI) ?","crawlDate":"2020-07-11T23:09:04.454829Z"},{"tags":["Biogen","Healthcare","Stock"],"id":26972839,"tickers":["biib"],"url":"https://finance.yahoo.com/news/biogen-approval-prospects-aducanumab-amount-003718853.html","description":"Not all biotechs are highflyers in 2020. Despite some pharma companies’ elevated coronavirus driven valuations, some have had to settle for more pedestrian performances.Take for instance biotech Biogen (BIIB). The large cap has had a middling 2020 so far, with shares down by 6% since the turn of the","publishedDate":"2020-07-11T00:37:18Z","source":"finance.yahoo.com","title":"Biogen: Approval Prospects for Aducanumab Amount to a Flip of a Coin, Says J.P. Morgan","crawlDate":"2020-07-11T01:01:02.122916Z"},{"tags":["Bausch Health","Bloomberg","ETF","Energy","Financial Services","Goldman Sachs","Healthcare","Stock","Technology","Unknown Sector","Utilities"],"id":26966729,"tickers":["abbv","amgn","antm","antx","biib","bmy","cvi","cxo","dkng","dvn","eog","fslr","gild","gs","gsbd","gsf","gsj","gvip","hfc","hum","lyft","mrk","pbf","pfe","pnw","regn","run","spwr","unh","vlo","vlp"],"url":"https://finance.yahoo.com/news/health-stocks-among-goldman-top-182613348.html","description":"(Bloomberg) -- U.S. equity investors are facing a turbulent four months as the presidential election heats up, and Goldman Sachs analysts scanned their coverage universe and found 38 stocks that investors can use to take advantage of that volatility with options.Large-cap health insurers and biotechs","publishedDate":"2020-07-10T18:26:13Z","source":"finance.yahoo.com","title":"Health Stocks Are Among Goldman’s Top Election Volatility Plays","crawlDate":"2020-07-10T19:04:04.766750Z"},{"tags":["All News And Stock Ideas","Auto Industry News & Stocks To Watch","Biotech And Pharma Stock News","Consumer Cyclical","Coronavirus","Defense And Aerospace Stocks And Industry News","Earnings","Facebook Stock News","Financial Services","Healthcare","Ibd Weekly Review","Industrials","News","Stock","Tech Earnings","Tesla Stock News","Utilities"],"id":26965039,"tickers":["amzn","ba","bhlb","biib","brk-a","brk-b","duk","dukh","gild","gnmk","lgih","nvax","pcp","qdel","regn"],"url":"https://www.investors.com/news/stock-market-rally-tesla-livongo-coronavirus-warren-buffett/","description":"The stock market rally had a mixed week amid soaring coronavirus cases, but tech giants and growth names ran higher. Warren Buffett finally made a big deal.","publishedDate":"2020-07-10T16:20:37Z","source":"investors.com","title":"Stock Market Rally Mixed, But Tesla, Livongo, Growth Names Power Past Coronavirus; Warren Buffett Makes A Deal","crawlDate":"2020-07-10T18:06:17.285750Z"},{"tags":["ETF","Financial Services","Healthcare","Stock","Unknown Sector"],"id":26961859,"tickers":["alrn","amjl","biib","cs"],"url":"https://www.smarteranalyst.com/new-blurbs/biogen-biib-gets-a-hold-rating-from-william-blair/","description":"In a report issued on July 8, Matt Phipps from William Blair maintained a Hold rating on Biogen (BIIB). The company's shares closed last Friday at","publishedDate":"2020-07-10T14:49:34Z","source":"smarteranalyst.com","title":"Biogen (BIIB) Gets a Hold Rating from William Blair","crawlDate":"2020-07-10T16:03:57.402854Z"},{"tags":["ETF","Financial Services","Healthcare","Stock","Top Market News","Unknown Sector"],"id":26960619,"tickers":["alrn","amjl","biib","cs"],"url":"https://www.analystratings.com/articles/biogen-biib-gets-a-hold-rating-from-william-blair/","description":"In a report issued on July 8,\nMatt Phipps\nfrom William Blair maintained a\nHold\nrating on Biogen (\nBIIB\n–\nResearch Report\n). The company’s shares closed last Friday at $277.41.\nAccording to\nTipRanks.com\n, Phipps is a 4-star analyst with an average ret","publishedDate":"2020-07-10T14:49:29Z","source":"analystratings.com","title":"Biogen (BIIB) Gets a Hold Rating from William Blair","crawlDate":"2020-07-10T15:12:41.094040Z"},{"tags":["Biib","Gild","Healthcare","Hot Stocks","Nasdaq:Biib","Nasdaq:Gild","Nasdaq:Regn","Regn","Stock"],"id":26955512,"tickers":["biib","gild","regn"],"url":"https://investorplace.com/2020/07/potential-alzheimers-drug-not-enough-to-excite-biogen-stock-investors/","description":"Biogen opened higher by around 10% on news of its Alzheimer's drug. By the end of day, Biogen stock gave up a bulk of its gains. What gives?","publishedDate":"2020-07-10T12:23:01Z","source":"investorplace.com","title":"Potential Alzheimer’s Drug Not Enough to Excite Biogen Stock Investors","crawlDate":"2020-07-10T12:25:20.884167Z"},{"tags":["Financial Services","Healthcare","Real Estate","Stock","Unknown Sector"],"id":26955192,"tickers":["alny","astx","azn","biib","blu","bmy","bx","bxmt","celg","celgz","clls","crvs","ct","dtil","gcvrz","gild","mdt","mkgaf","mrk","nvax","pfe","regn","reta","sny","zeal"],"url":"https://xconomy.com/national/2020/07/10/bio-roundup-blackstones-billions-biogen-finishes-filing-novavax-at-warp-speed-more/","description":"Cash flowed throughout the life sciences ecosystem this week as Blackstone (NYSE: ]) raised a record-setting life sciences fund, companies of all stages","publishedDate":"2020-07-10T12:15:27Z","source":"xconomy.com","title":"Bio Roundup: Blackstone's Billions, Biogen Finishes Filing, Novavax at \"Warp Speed\" & More","crawlDate":"2020-07-10T12:18:13.477720Z"},{"tags":["Healthcare","Stock","Unknown Sector"],"id":26956709,"tickers":["bhvn","biib","bmrn","itci","stok","zyne"],"url":"https://www.smarteranalyst.com/new-blurbs/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-stoke-therapeutics-stok/","description":"There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Stoke Therapeutics (STOK) with bullish","publishedDate":"2020-07-10T10:06:34Z","source":"smarteranalyst.com","title":"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Stoke Therapeutics (STOK)","crawlDate":"2020-07-10T13:02:05.050628Z"},{"tags":["Biib","Biogen","Healthcare","Nasdaq:Biib","Stock","Sumant Kulkarni","Unknown Sector"],"id":26950377,"tickers":["bhvn","biib","bmrn","itci","stok","zyne"],"url":"https://www.markets.co/analysts-offer-insights-on-healthcare-companies-biogen-nasdaq-biib-and-stoke-therapeutics-nasdaq-stok/260747/","description":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB","publishedDate":"2020-07-10T10:06:31Z","source":"markets.co","title":"Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Stoke Therapeutics (NASDAQ: STOK)","crawlDate":"2020-07-10T10:09:48.032923Z"},{"tags":["09062X10","Biib","Biogen","Call","Communication Services","Healthcare","Medical","Nasdaq:Biib","Options","Put","Stock","Stocks"],"id":26947063,"tickers":["biib","call"],"url":"https://www.thelincolnianonline.com/2020/07/10/traders-purchase-high-volume-of-call-options-on-biogen-nasdaqbiib.html","description":"Biogen Inc (NASDAQ:BIIB) was the recipient of unusually large options trading activity on Wednesday. Traders bought 26,549 call options on the stock. This is an increase of approximately 400% compared to the average volume of 5,309 call options. Shares of BIIB stock opened at $278.70 on Friday. The firm has a market cap of $43.79 […]","publishedDate":"2020-07-10T08:12:49Z","source":"thelincolnianonline.com","title":"Traders Purchase High Volume of Call Options on Biogen (NASDAQ:BIIB)","crawlDate":"2020-07-10T08:36:18.382393Z"},{"tags":["Biomarin Pharmaceutical Inc","Companies","Financial Services","Food And Drug Administration","Healthcare","Hemophilia A","Pfizer Inc","Pharmaceutical Companies","Stock","Unknown Sector"],"id":26932947,"tickers":["abbv","bayry","bayzf","biib","blue","bmrn","bmy","gild","glaxf","glpg","glpgf","gsk","ions","jpm","jpm-ws","lly","nvo","nvs","nvsef","pfe","ptct","regn","rhhby","rhhvf","sgen","srpt"],"url":"https://finance.yahoo.com/news/biomarins-hemophilia-drug-among-5-195724584.html","description":"If approved, company’s Roctavian would become first gene therapy for inherited disease Continue reading...","publishedDate":"2020-07-09T19:57:24Z","source":"finance.yahoo.com","title":"Biomarin's Hemophilia A Drug Among 5 Up for FDA Approval Soon","crawlDate":"2020-07-09T20:00:34.567398Z"},{"tags":["Coronavirus","Donald Trump","Government Agencies","Healthcare","Stock","Technology","The Readout Loud","Vaccines","White House"],"id":26932342,"tickers":["biib","goog","googl"],"url":"https://www.statnews.com/2020/07/09/podcast-trump-fda-pressure-pandemic-covid-19-vaccine/","description":"In this episode, STAT's Nicholas Florko joins us to explain how mounting pressure from President Trump is affecting the FDA and the CDC.","publishedDate":"2020-07-09T19:28:04Z","source":"statnews.com","title":"Listen: Trump’s FDA pressure, a microcosm of the pandemic, and squabbling over a vaccine","crawlDate":"2020-07-09T19:29:35.030587Z"},{"tags":["Biogen","Boston","Consumer Cyclical","Healthcare","Massachusetts","Stock"],"id":26931331,"tickers":["biib","mar","vac"],"url":"https://finance.yahoo.com/news/city-home-superspreader-hotel-hospitality-183010966.html","description":"Boston travel organizations know they have a giant thorn from their past to overcome for state officials to green light a plan to once again allow the private events and meetings the state’s largest hotels need in order to survive. A Biogen conference at the Boston Marriott Long Wharf hotel in late February","publishedDate":"2020-07-09T18:30:10Z","source":"finance.yahoo.com","title":"Your City Was Home to a Superspreader Hotel: What Hospitality Can Learn From Boston’s Comeback Plan","crawlDate":"2020-07-09T18:47:30.317901Z"},{"tags":["Biogen","Biotech","Boston","Bristol-Myers Squibb Company","Business","Consumer Cyclical","Curevac Ag","Dragonfly Therapeutics","Health","Healthcare","Inc.","Inozyme Pharma Inc.","Insurance","Massachusetts","Pharmaceuticals","Private Equity","Ra Capital Management","Sanofi Us Services Inc.","Sarepta Therapeutics Inc.","Stock","Tesla Inc."],"id":26926250,"tickers":["biib","bmy","mrk","srpt","tsla"],"url":"https://www.bizjournals.com/boston/news/2020/07/09/petri-dish-deals-and-alzheimers-drug-application.html","description":"This week, biopharma companies signed new partnership and licensing deals worth $890 million and another company disclosed IPO plans.","publishedDate":"2020-07-09T15:29:05Z","source":"bizjournals.com","title":"The Petri Dish: $890M in new deals and an Alzheimer's drug application","crawlDate":"2020-07-09T16:01:55.301245Z"},{"tags":["Aducanumab","Alzheimer’S Disease","Biogen","Biologics License Application","Fda","Healthcare","Stock","Unknown Sector"],"id":26920559,"tickers":["azn","biib","esaly","mkgaf","mrk","pfe"],"url":"https://finance.yahoo.com/news/biogen-files-bla-alzheimers-drug-121112384.html","description":"If Biogen's (BIIB) aducanumab is approved by the FDA, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.","publishedDate":"2020-07-09T12:11:12Z","source":"finance.yahoo.com","title":"Biogen Files BLA for Alzheimer's Drug Aducanumab, Stock Up","crawlDate":"2020-07-09T13:19:02.570820Z"},{"tags":["Analyst Blog","Healthcare","Stock"],"id":26920027,"tickers":["amgn","biib","nvs","rhhby"],"url":"https://www.zacks.com/stock/news/1000689/biogen-files-bla-for-alzheimers-drug-aducanumab-stock-up?cid=CS-ZC-FT-analyst_blog%7Ccompany_news_-_medical_sector-1000689","description":"If Biogen's (BIIB) aducanumab is approved by the FDA, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.","publishedDate":"2020-07-09T12:11:00Z","source":"zacks.com","title":"Biogen Files BLA for Alzheimer's Drug Aducanumab, Stock Up","crawlDate":"2020-07-09T13:03:16.744035Z"},{"tags":["Healthcare","Industrials","Nasdaq","Nyse","Pharmaceutical Company","Stock","Unknown Sector"],"id":26925261,"tickers":["acer","akro","alt","amyt","anab","apdn","argx","asmb","azn","bbi","bhvn","biib","bvxv","crsp","csii","cytk","ebs","fold","gmab","gnmk","icpt","immu","lly","mcrb","mgnx","mrsn","neo","nk","nnvc","ntla","opk","optn","oric","osmt","otic","pcrx","pypd","qdel","qlgn","rvmd","swav","syrs","tak","tgtx","tkphf","twst","vbiv","vvusq","zlab"],"url":"https://finance.yahoo.com/news/daily-biotech-pulse-fda-nod-120942410.html","description":"Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)  * Akero Therapeutics Inc (NASDAQ: AKRO)  * Altimmune Inc (NASDAQ: ALT)  * Amicus Therapeutics, Inc. (NASDAQ: FOLD)  * AMRYT PHARMA PL/S ADR (NASDAQ: AMYT","publishedDate":"2020-07-09T12:09:42Z","source":"finance.yahoo.com","title":"The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio","crawlDate":"2020-07-09T15:28:48.188296Z"},{"tags":["Healthcare","Institutional Investors","Institutions","Sangamo Therapeutics","Stock"],"id":26919179,"tickers":["biib","sgmo"],"url":"https://finance.yahoo.com/news/many-sangamo-therapeutics-inc-nasdaq-114329083.html","description":"Every investor in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) should be aware of the most powerful shareholder groups...","publishedDate":"2020-07-09T11:43:29Z","source":"finance.yahoo.com","title":"How Many Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Do Institutions Own?","crawlDate":"2020-07-09T12:37:00.245687Z"},{"tags":["Alzheimer’S","Amyotrophic Lateral Sclerosis","Clinical Development","Frontotemporal Dementia","Healthcare","Immune Cell","Myeloid Cells","Nervous System Disorders","Neurodegenerative","Orphan Diseases","Stanford University","Stock","Unknown Sector"],"id":26916415,"tickers":["amgn","biib","dndn"],"url":"https://finance.yahoo.com/news/tranquis-therapeutics-launches-30-million-110000842.html","description":"Tranquis launched with $30M in Series A funding to develop therapeutics with potential to revolutionize the management of neurodegenerative diseases","publishedDate":"2020-07-09T11:00:00Z","source":"finance.yahoo.com","title":"Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology Approach to Treating Neurodegenerative and Aging-related Diseases","crawlDate":"2020-07-09T11:28:49.626269Z"},{"tags":["Btc Price","Chancellor Sunak","Consumer Cyclical","Consumer Defensive","CryptoCurrency","Ftse","Healthcare","Industrials","Markets","Stock","Technology","United Airlines","Unknown Sector","Utilities","Walgreens Boots"],"id":26930840,"tickers":["aal","bbby","biib","dal","deltw","dgas","icagy","nvda","wba"],"url":"https://www.leaprate.com/forex/market-news/daily-market-news-united-airlines-signals-plans-to-lay-off-nearly-50-of-staff/","description":"What to watch Walgreens Boots: This week, pharmacy retailer Walgreens Boots announced it has reached a deal with a primary care firm to open doctors’","publishedDate":"2020-07-09T10:35:50Z","source":"leaprate.com","title":"Daily Market News: United Airlines signals plans to lay off nearly 50% of staff","crawlDate":"2020-07-09T18:27:30.783284Z"},{"tags":["Aducanumab","Alzheimer’S Disease","Biogen","Biologics License Application","Financial Services","Food And Drug Administration","Healthcare","Stock","Unknown Sector"],"id":26912663,"tickers":["biib","gs","gsbd","gsf","gsj"],"url":"https://finance.yahoo.com/news/biogen-files-fda-application-potential-090659261.html","description":"Biogen Inc. (BIIB) announced that it has finally submitted the Biologics License Application (BLA) seeking approval by the Food and Drug Administration (FDA) for aducanumab, its investigational treatment for Alzheimer’s disease.If approved, aducanumab would become the first therapy to reduce the clinical","publishedDate":"2020-07-09T09:06:59Z","source":"finance.yahoo.com","title":"Biogen Files FDA Application For Potential Alzheimer Treatment","crawlDate":"2020-07-09T09:42:56.888739Z"},{"tags":["Financial Services","Healthcare","Stock","Unknown Sector"],"id":26912451,"tickers":["biib","gs","gsbd","gsf","gsj"],"url":"https://www.smarteranalyst.com/stock-news/biogen-files-fda-application-for-potential-alzheimer-treatment/","description":"Biogen Inc. (BIIB) announced that it has finally submitted the Biologics License Application (BLA) seeking approval by the Food and Drug Administration","publishedDate":"2020-07-09T09:06:59Z","source":"smarteranalyst.com","title":"Biogen Files FDA Application For Potential Alzheimer Treatment","crawlDate":"2020-07-09T09:36:30.265973Z"},{"tags":["Aducanumab","Alzheimer'S","Biogen","Eisai","Healthcare","Neurology","News","Stock","Unknown Sector"],"id":26911449,"tickers":["biib","esaly"],"url":"https://pharmaphorum.com/news/biogen-shares-pop-as-it-completes-filing-for-alzheimers-drug-aducanumab/","description":"Biogen’s share price was up sharply on Wednesday after the big pharma completed its filing of its Alzheimer’s Disease (AD) drug aducanumab with the FDA. ","publishedDate":"2020-07-09T08:53:28Z","source":"pharmaphorum.com","title":"Biogen shares pop as it completes filing for Alzheimer’s drug aducanumab","crawlDate":"2020-07-09T09:04:59.281794Z"},{"tags":["09062X10","Biib","Biogen","Financial Services","Healthcare","Medical","Nasdaq:Biib","Reiterated Rating","Stock","Suntrust Banks Inc."],"id":26910240,"tickers":["biib","sti"],"url":"https://www.thelincolnianonline.com/2020/07/09/biogen-nasdaqbiib-stock-rating-reaffirmed-by-suntrust-banks.html","description":"Biogen (NASDAQ:BIIB)‘s stock had its “buy” rating reissued by analysts at SunTrust Banks in a report issued on Wednesday, TipRanks reports. They presently have a $330.00 target price on the biotechnology company’s stock. SunTrust Banks’ target price indicates a potential upside of 17.78% from the company’s previous close. Other research analysts have also issued research […]","publishedDate":"2020-07-09T07:46:42Z","source":"thelincolnianonline.com","title":"Biogen (NASDAQ:BIIB) Stock Rating Reaffirmed by SunTrust Banks","crawlDate":"2020-07-09T08:19:39.209356Z"},{"tags":["Healthcare","Japan","Reu","Stock","Unknown Sector"],"id":26909340,"tickers":["biib","esaly","sftbf"],"url":"https://business.financialpost.com/pmn/business-pmn/japanese-shares-rebound-but-spike-in-covid-19-cases-caps-gains","description":"TOKYO — Japanese shares bounced back on Thursday buoyed by technology-related stocks following a rise in U.S. peers overnight, but gains were limited by a surge in domestic coronavirus cases.…","publishedDate":"2020-07-09T07:37:31Z","source":"financialpost.com","title":"Japanese shares rebound but spike in COVID-19 cases caps gains","crawlDate":"2020-07-09T07:44:13.487921Z"},{"tags":["Coronavirus Cases","Healthcare","Japan","Nikkei Index","Stock","Unknown Sector"],"id":26909713,"tickers":["biib","esaly","sftbf"],"url":"https://finance.yahoo.com/news/japanese-shares-rebound-spike-covid-073541676.html","description":"Japanese shares bounced back on Thursday buoyed by technology-related stocks following a rise in U.S. peers overnight, but gains were limited by a surge in domestic coronavirus cases.  The benchmark Nikkei share average rose 0.4% to 22,529.29, clawing back from a 0.78% drop in the previous session.","publishedDate":"2020-07-09T07:35:41Z","source":"finance.yahoo.com","title":"Japanese shares rebound but spike in COVID-19 cases caps gains","crawlDate":"2020-07-09T07:59:26.657171Z"},{"tags":["09062X10","Biib","Biogen","ETF","Financial Services","Guggenheim","Healthcare","Medical","Nasdaq:Biib","Reiterated Rating","Stock","Unknown Sector"],"id":26909550,"tickers":["bcf","bgio","biib","blk","c","sti","stt"],"url":"https://www.thelincolnianonline.com/2020/07/09/biogen-nasdaqbiib-stock-rating-reaffirmed-by-guggenheim.html","description":"Biogen (NASDAQ:BIIB)‘s stock had its “buy” rating reaffirmed by research analysts at Guggenheim in a research report issued on Wednesday, TipRanks reports. They presently have a $390.00 price objective on the biotechnology company’s stock. Guggenheim’s target price would suggest a potential upside of 39.19% from the stock’s current price. Other equities research analysts have also […]","publishedDate":"2020-07-09T07:14:45Z","source":"thelincolnianonline.com","title":"Biogen (NASDAQ:BIIB) Stock Rating Reaffirmed by Guggenheim","crawlDate":"2020-07-09T07:51:58.328310Z"},{"tags":["Aducanumab","Alzheimer","Biogen Inc","Financial Services","Healthcare","Stock","United States","Unknown Sector"],"id":26905446,"tickers":["biib","cown","cownl","esaly"],"url":"https://finance.yahoo.com/news/biogen-moves-forward-potential-alzheimers-042353316.html","description":"Biogen shares were up nearly 5% at $281.34 in afternoon trading on the Nasdaq.  The number of people in the United States living with Alzheimer's, the most common form of dementia, is expected to triple to nearly 14 million by 2050 without effective treatments, according to the U.S. Centers for Disease","publishedDate":"2020-07-09T04:23:53Z","source":"finance.yahoo.com","title":"Biogen moves forward with potential Alzheimer's drug, seeks U.S. approval","crawlDate":"2020-07-09T04:31:20.543652Z"},{"tags":["Healthcare","Japan","Reu","Stock","Unknown Sector"],"id":26904981,"tickers":["biib","esaly","sftbf"],"url":"https://business.financialpost.com/pmn/business-pmn/nikkei-rebounds-as-tech-related-shares-gain","description":"TOKYO — Japan’s Nikkei share average bounced back on Thursday, powered by technology-related stocks following strong gains in U.S. peers overnight.The benchmark Nikkei share average ros…","publishedDate":"2020-07-09T03:47:11Z","source":"financialpost.com","title":"Nikkei rebounds as tech-related shares gain","crawlDate":"2020-07-09T03:51:06.482968Z"},{"tags":["Healthcare","Japan","Nikkei Index","Stock","Unknown Sector"],"id":26905148,"tickers":["biib","esaly","sftbf"],"url":"https://finance.yahoo.com/news/nikkei-rebounds-tech-related-shares-034615821.html","description":"Japan's Nikkei share average bounced back on Thursday, powered by technology-related stocks following strong gains in U.S. peers overnight.  The benchmark Nikkei share average rose 0.21% to 22,486.01 by the midday break, partially clawing back from a 0.78% drop in the previous session.  On the Nikkei","publishedDate":"2020-07-09T03:46:15Z","source":"finance.yahoo.com","title":"Nikkei rebounds as tech-related shares gain","crawlDate":"2020-07-09T04:09:40.482899Z"},{"tags":["Consumer Cyclical","Dow Jones","Financial Services","Healthcare","Nasdaq","S P500","Stock","Technology","Unknown Sector","Us Markets","Wall Street"],"id":26904289,"tickers":["aapl","all","amzn","biib","msft","nghc","nghcz"],"url":"https://www.moneycontrol.com/news/business/markets/nasdaq-ends-at-record-high-as-wall-street-rises-with-tech-shares-5525451.html","description":"The Dow Jones Industrial Average rose 177.1 points, or 0.68%, to 26,067.28, the S&P 500 gained 24.62 points, or 0.78%, to 3,169.94 and the Nasdaq Composite added 148.61 points, or 1.44%, to 10,492.50.","publishedDate":"2020-07-09T02:23:18Z","source":"moneycontrol.com","title":"Nasdaq ends at record high as Wall Street rises with tech shares","crawlDate":"2020-07-09T02:36:25.335365Z"},{"tags":["Healthcare","Stock","Unknown Sector"],"id":26901934,"tickers":["biib","esaly"],"url":"https://xconomy.com/boston/2020/07/08/biogen-alzheimers-drug-in-fdas-court-following-completion-of-filing/","description":"By early September Biogen---plus the many scientists, patients, and investors following the saga of its controversial Alzheimer’s drug aducanamab---should","publishedDate":"2020-07-08T22:51:51Z","source":"xconomy.com","title":"Biogen Alzheimer’s Drug in FDA's Court Following Completion of Filing","crawlDate":"2020-07-08T22:55:58.803245Z"},{"tags":["Headlines","Healthcare","Stock","Tiingo Top"],"id":26902123,"tickers":["biib"],"url":"https://www.reuters.com/article/brief-the-new-england-journal-of-medicin/brief-the-new-england-journal-of-medicine-publishes-final-results-from-phase-1-2-study-oftofersen-for-a-genetic-form-of-als-idUSFWN2EF0R2","description":"Biogen Inc:","publishedDate":"2020-07-08T22:18:58Z","source":"reuters.com","title":"BRIEF-The New England Journal Of Medicine Publishes Final Results From Phase 1/2 Study OfTofersen For A Genetic Form Of ALS","crawlDate":"2020-07-08T23:06:29.720440Z"}]
